GLPwatch
Victoza for Chronic kidney disease
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCVictoza (liraglutide) is not FDA-approved for chronic kidney disease, and any use for this condition is off-label or investigational. Research includes studies on its effects on kidney outcomes in type 2 diabetes and animal models, but these do not establish approval for treating chronic kidney disease.
AI summary of the sources below.
| Drug | Victoza (liraglutide) |
|---|---|
| Condition | Chronic kidney disease |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Victoza is not FDA-approved for chronic kidney disease; the research below reflects investigational or off-label study only.
Research on liraglutide for chronic kidney disease (50)
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- The Discovery and Development of Liraglutide and Semaglutide.
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
- Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
- Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
- Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis.
- Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
- The effect of liraglutide on renal function: A randomized clinical trial.
- Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
- Liraglutide: the therapeutic promise from animal models.
- Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.
- The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis.
- Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells.
- Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
- Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.
- Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.
- The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
- Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.
- Mild renal impairment and the efficacy and safety of liraglutide.